EOC 237
Alternative Names: EOC-237Latest Information Update: 25 Aug 2023
At a glance
- Originator Shanghai Yiteng Jingang Bio-pharmaceutical Technology
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 26 Jul 2023 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (PO) (NCT05895825)
- 12 Jun 2023 Preclinical trials in Solid tumours in China (PO)
- 12 Jun 2023 Shanghai Yiteng Jingang Bio-pharmaceutical Technology plans a phase I trial for Solid tumours (Late-stage disease) in June 2023 (PO) (NCT05895825)